keyword
MENU ▼
Read by QxMD icon Read
search

Emtricitabine

keyword
https://www.readbyqxmd.com/read/29147636/drug-induced-lupus-erythematosus-associated-with-antiretroviral-therapy-in-a-patient-with-human-immunodeficiency-virus-a-case-report
#1
Jazila Mantis, Ravi Bhavsar, Adriana Abrudescu
Antiretroviral medications are the mainstay of human immunodeficiency virus (HIV) therapy and some have been in use for over 20 years. To date, there have been no reported cases of antiretroviral therapy (ART) induced drug-induced lupus erythematosus (DILE). We present a case of a 35-year-old woman who received a combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate for HIV treatment. Three years later, she developed an extensive rash and polyarthralgia in her extremities with laboratory findings significant for positive antinuclear antibody (ANA), anti-double stranded deoxyribonucleic acid (DNA) antibody (anti-dsDNA), and anti-histone antibody titers...
September 7, 2017: Curēus
https://www.readbyqxmd.com/read/29145807/durability-of-switch-regimens-based-on-rilpivirine-or-on-integrase-inhibitors-both-in-association-with-tenofovir-and-emtricitabine-in-hiv-infected-virologically-suppressed-patients
#2
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virologically suppressed, HIV-infected patients. METHODS: Retrospective analysis of patients who started rilpivirine or an InSTI (both with tenofovir and emtricitabine) with <50 HIV-RNA copies/mL and had at least one HIV-RNA assessed while receiving the study regimen...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143565/hiv-1-resistance-rarely-observed-in-subjects-using-darunavir-once-daily-regimens-across-clinical-studies
#3
Erkki Lathouwers, Eric Y Wong, Donghan Luo, Sareh Seyedkazemi, Sandra De Meyer, Kimberley Brown
BACKGROUND: Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without darunavir resistance-associated mutations [RAMs]) individuals, and has been evaluated in phase 2/3 studies with durations between 48 and 192 weeks. OBJECTIVE: To summarize the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among subjects receiving darunavir QD dosing. METHODS: Seven phase 2/3 studies with available genotypes/phenotypes for subjects treated with ritonavir- or cobicistat-boosted darunavir 800 mg QD regimens were assessed: ARTEMIS (NCT00258557; n = 343), GS-US-299-0102 (NCT01565850; n = 153), GS-US-216-0130 (NCT01440569; n = 313), ODIN (NCT00524368; n = 294), INROADS (NCT01199939; n = 54), MONET (NCT00458302; n = 256), and PROTEA (NCT01448707; n = 273)...
November 16, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/29135651/comparison-of-the-pharmacokinetics-and-pharmacodynamics-of-single-dose-tenofovir-vaginal-film-and-gel-formulation-fame-05
#4
Jennifer A Robinson, Mark A Marzinke, Edward J Fuchs, Rahul P Bakshi, Hans M L Spiegel, Jenell S Coleman, Lisa C Rohan, Craig W Hendrix
OBJECTIVE: While pre-exposure prophylaxis with oral tenofovir (TFV) disoproxil fumarate/emtricitabine reduces HIV acquisition rates, poor adherence to and acceptability of daily vaginal gels has led to development of vaginal film formulations to improve adherence and, potentially, enable episodic use. STUDY DESIGN: In this two-arm, cross-over study of a fast-dissolving tenofovir film (40 mg) compared to a previously studied semisolid tenofovir 1% gel (40 mg), 10 healthy women received a single vaginal dose of each study product...
November 7, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29126456/virological-response-hiv-1-drug-resistance-mutations-and-genetic-diversity-among-patients-on-first-line-antiretroviral-therapy-in-n-djamena-chad-findings-from-a-cross-sectional-study
#5
Chatté Adawaye, Joseph Fokam, Erick Kamangu, Hamit Mahamat Alio, Aoudalkarim Moussa Chahad, Fabrice Susin, Ali Mahamat Moussa, Tchombou Hig-Zounet Bertin, Abdelsalam Tidjani, Dolores Vaira, Michel Moutschen
BACKGROUND: The national antiretroviral therapy in the Republic of Chad provides free of charge antiretroviral regimens and therapeutic monitoring for patients receiving antiretroviral therapy nationwide. For a successful programmatic uptake, these efforts merit to be supported by thorough assessments of antiretroviral therapy response and HIV-1 drug resistance surveillance, especially with risks of cross-resistance due to the gradual stavudine phasing out in such national settings. We therefore evaluated the virological response to antiretroviral therapy, HIV-1 drug resistance emergence and circulating HIV-1 clades in a Chad context...
November 10, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29126299/cns-penetration-of-art-in-hiv-infected-children
#6
Malon Van den Hof, Charlotte Blokhuis, Sophie Cohen, Henriette J Scherpbier, Ferdinand W N M Wit, M C M Pistorius, Neeltje A Kootstra, Charlotte E Teunissen, Ron A A Mathot, Dasja Pajkrt
Background: Paediatric data on CNS penetration of antiretroviral drugs are scarce. Objectives: To evaluate CNS penetration of antiretroviral drugs in HIV-infected children and explore associations with neurocognitive function. Patients and methods: Antiretroviral drug levels were measured in paired CSF and blood samples of clinically stable HIV-infected children between 8 and 18 years old on long-term combined ART. Plasma drug concentrations were corrected for protein binding...
November 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29119473/preference-of-oral-tenofovir-disoproxil-fumarate-emtricitabine-versus-rectal-tenofovir-reduced-glycerin-1-gel-regimens-for-hiv-prevention-among-cisgender-men-and-transgender-women-who-engage-in-receptive-anal-intercourse-with-men
#7
Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, Cheng-Shiun Leu, Iván C Balán, William Brown, Christine Rael, Barbra A Richardson, Jeanna M Piper, Linda-Gail Bekker, Suwat Chariyalertsak, Anupong Chitwarakorn, Pedro Gonzales, Timothy H Holtz, Albert Liu, Kenneth H Mayer, Carmen D Zorrilla, Javier R Lama, Ian McGowan, Ross D Cranston
Oral pre-exposure prophylaxis (PrEP) can prevent HIV transmission. Yet, some may prefer not to take systemic daily medication. MTN-017 was a 3-period, phase 2 safety and acceptability study of microbicide gel applied rectally either daily or before and after receptive anal intercourse (RAI), compared to daily oral tablet. At baseline, cisgender men and transgender women who reported RAI (N = 187) rated the daily oral regimen higher in overall liking, ease of use, and likelihood of future use than the gel regimens...
November 8, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/29112956/hiv-1-persistence-following-extremely-early-initiation-of-antiretroviral-therapy-art-during-acute-hiv-1-infection-an-observational-study
#8
Timothy J Henrich, Hiroyu Hatano, Oliver Bacon, Louise E Hogan, Rachel Rutishauser, Alison Hill, Mary F Kearney, Elizabeth M Anderson, Susan P Buchbinder, Stephanie E Cohen, Mohamed Abdel-Mohsen, Christopher W Pohlmeyer, Remi Fromentin, Rebecca Hoh, Albert Y Liu, Joseph M McCune, Jonathan Spindler, Kelly Metcalf-Pate, Kristen S Hobbs, Cassandra Thanh, Erica A Gibson, Daniel R Kuritzkes, Robert F Siliciano, Richard W Price, Douglas D Richman, Nicolas Chomont, Janet D Siliciano, John W Mellors, Steven A Yukl, Joel N Blankson, Teri Liegler, Steven G Deeks
BACKGROUND: It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART...
November 2017: PLoS Medicine
https://www.readbyqxmd.com/read/29112071/the-role-of-menopause-in-tenofovir-diphosphate-and-emtricitabine-triphosphate-concentrations-in-cervical-tissue
#9
Melanie R Nicol, Lindsey M Brewers, Angela Dm Kashuba, Craig Sykes
OBJECTIVE: Although postmenopausal women have behavioral and biological risk factors for HIV infection, the activity of pre-exposure prophylaxis agents in older adults has not been well studied. DESIGN: We used an ex-vivo approach to compare the tissue concentrations of tenofovir diphosphate (TFVdp) and emtricitabine triphosphate (FTCtp) in cervical tissues from premenopausal and postmenopausal women. METHOD: Cervical explants from 16 premenopausal and 11 postmenopausal women were incubated in 10-300 μg/mL tenofovir or emtricitabine for 24 hours...
November 2, 2017: AIDS
https://www.readbyqxmd.com/read/29112066/emulating-a-target-trial-of-antiretroviral-therapy-regimens-started-before-conception-and-risk-of-adverse-birth-outcomes
#10
Ellen C Caniglia, Rebecca Zash, Denise L Jacobson, Modiegi Diseko, Gloria Mayondi, Shahin Lockman, Jennifer Chen, Mompati Mmalane, Joseph Makhema, Miguel A Hernán, Roger L Shapiro
OBJECTIVE: To compare the effect of pre-conception initiation of zidovudine, lamivudine, nevirapine (ZDV/3TC/NVP) versus tenofovir, emtricitabine, efavirenz (TDF/FTC/EFV) on adverse birth outcomes. DESIGN: Emulation of a hypothetical (target) trial using a birth surveillance study in Botswana during an era of CD4-based antiretroviral therapy (ART) initiation. METHODS: In women who initiated ART < 3 years from HIV diagnosis, conceived 0...
November 2, 2017: AIDS
https://www.readbyqxmd.com/read/29110395/antiretroviral-pill-count-and-clinical-outcomes-in-treatment-na%C3%A3-ve-patients-with-hiv-infection
#11
J Young, C Smith, R Teira, P Reiss, I Jarrín Vera, H Crane, J M Miro, A D'Arminio Monforte, M Saag, R Zangerle, H C Bucher
OBJECTIVES: Treatment guidelines recommend single-tablet regimens for patients with HIV infection starting antiretroviral therapy. These regimens might be as effective and cost less if taken as separate drugs. We assessed whether the one pill once a day combination of efavirenz, emtricitabine and tenofovir reduces the risk of disease progression compared with multiple-pill formulations of the same regimen. METHODS: We selected treatment-naïve patients starting one-, two- or three-pill formulations of this regimen in data from the Antiretroviral Therapy Cohort Collaboration...
November 6, 2017: HIV Medicine
https://www.readbyqxmd.com/read/29105160/strength-in-amalgamation-newer-combination-agents-for-hiv-and-implications-for-practice
#12
Christopher McCoy, Melissa Badowski, Elizabeth Sherman, Rustin Crutchley, Ethan Smith, Daniel B Chastain
Antiretroviral (ART) therapy for treatment of human immunodeficiency virus (HIV) infection has undergone significant changes over the past 30 years. Many single tablet regimens (STR), including newer fixed dose combination (FDC) tablets, are available, offering patients several options for choosing a treatment regimen that works best for them. Given these changes, patients are more likely to adhere to treatment, achieve better clinical outcomes, and experience both fewer side effects and drug-drug interactions...
November 3, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29100029/validation-of-an-lc-ms-ms-assay-to-simultaneously-monitor-the-intracellular-active-metabolites-of-tenofovir-emtricitabine-and-lamivudine-in-dried-blood-spots
#13
Amanda P Schauer, Craig Sykes, Mackenzie L Cottrell, Heather Prince, Angela D M Kashuba
The ability to monitor adherence to antiretroviral therapy is critical for the interpretation of outcomes from clinical studies of HIV, and for optimizing patient care. The antiretrovirals tenofovir (TFV), emtricitabine (FTC), and lamivudine (3TC) are commonly included in drug regimens for HIV prevention and treatment. The active form of the drugs tenofovir diphosphate (TFVdp), emtricitabine triphosphate (FTCtp), and lamivudine triphosphate (3TCtp) are found intracellularly in erythrocytes and peripheral blood mononuclear cells (PBMCs)...
October 31, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29096670/hiv-treatment-simplification-to-elvitegravir-cobicistat-emtricitabine-tenofovir-disproxil-fumarate-e-c-f-tdf-plus-darunavir-a-pharmacokinetic-study
#14
Marianne Harris, Bruce Ganase, Birgit Watson, P Richard Harrigan, Julio S G Montaner, Mark W Hull
BACKGROUND: As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and pharmacokinetics of once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) with darunavir. METHODS: A single arm, open-label 48-week study was conducted of regimen simplification to E/C/F/TDF plus darunavir 800 mg daily from stable therapy including two nucleoside/nucleotide reverse transcriptase inhibitors, a ritonavir-boosted protease inhibitor, and an integrase inhibitor...
November 2, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/29091217/tenofovir-disoproxil-fumarate-emtricitabine-plus-ritonavir-boosted-lopinavir-or-cobicistat-boosted-elvitegravir-as-a-single-tablet-regimen-for-hiv-post-exposure-prophylaxis
#15
A Inciarte, L Leal, E González, A León, C Lucero, J Mallolas, B Torres, M Laguno, J Rojas, M Martínez-Rebollar, A González-Cordón, A Cruceta, J A Arnaiz, J M Gatell, F García
Objectives: To assess HIV-1 post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus cobicistat-boosted elvitegravir as a single-tablet regimen (STR), using tenofovir disoproxil fumarate/emtricitabine with both of these therapies. Methods: A prospective, open, randomized clinical trial was performed. Individuals attending the emergency room due to potential sexual exposure to HIV and who met criteria for PEP were randomized 1:3 into two groups receiving either 400/100 mg of lopinavir/ritonavir (n = 38) or 150/150 mg of elvitegravir/cobicistat (n = 119), with both groups also receiving 245/200 mg of tenofovir disoproxil fumarate/emtricitabine...
October 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29090394/utility-of-different-adherence-measures-for-prep-patterns-and-incremental-value
#16
Andrew Abaasa, Craig Hendrix, Monica Gandhi, Peter Anderson, Anatoli Kamali, Freddie Kibengo, Eduard J Sanders, Gaudensia Mutua, Namandjé N Bumpus, Frances Priddy, Jessica E Haberer
Measuring PrEP adherence remains challenging. In 2009-2010, the International AIDS Vaccine Initiative randomized phase II trial participants to daily tenofovir disoproxil fumarate/emtricitabine or placebo in Uganda and Kenya. Adherence was measured by electronic monitoring (EM), self-report (SR), and drug concentrations in plasma and hair. Each adherence measure was categorised as low, moderate, or high and also considered continuously; the incremental value of combining measures was determined. Forty-five participants were followed over 4 months...
October 31, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/29076032/brief-participant-centered-convergence-interviews-integrate-self-reports-product-returns-and-pharmacokinetic-results-to-improve-adherence-measurement-in-mtn-017
#17
Iván C Balán, Rebecca Giguere, William Brown, Alex Carballo-Diéguez, Stephanie Horn, Craig W Hendrix, Mark A Marzinke, Ratiya Pamela Kunjara Na Ayudhya, Karen Patterson, Jeanna M Piper, Ian McGowan, Javier R Lama, Ross D Cranston
MTN-017 compared the safety and acceptability of daily oral emtricitabine/tenofovir disoproxil fumarate, daily reduced-glycerin 1% tenofovir gel applied rectally, and the same gel applied before and after receptive anal intercourse. The Data Convergence Interview (DCI) and the Pharmacokinetic Data Convergence Interview (PK-DCI) were brief, collaborative interactions conducted with participants during adherence counseling sessions to improve accurate measurement of adherence to study product use. DCIs converged data from product return counts and participants' responses to daily text messages...
October 26, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/29071467/raltegravir-once-daily-tablet-a-review-in-hiv-1-infection
#18
Emma D Deeks
A once-daily tablet formulation (Isentress(®) HD; Isentress(®) 600 mg) of the integrase strand transfer inhibitor raltegravir is now available for the treatment of HIV-1 infection. The 600 mg tablet has improved bioavailability versus the existing twice-daily 400 mg tablet (due, at least in part, to differences in tablet dissolution) and the recommended dosage is 1200 mg (i.e. two 600 mg tablets) once daily. In combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve adults, once-daily raltegravir 1200 mg provided virological suppression non-inferior to that seen with twice-daily raltegravir 400 mg over 48 and 96 weeks in the phase 3 ONCEMRK trial...
October 2017: Drugs
https://www.readbyqxmd.com/read/29066858/rilpivirine-the-key-for-long-term-success
#19
Pompeyo Viciana
During the past 30 years of antiretroviral therapy, continuous improvements in drug discovery have provided increasingly potent and safer antivirals that have transformed HIV infection in a chronic illness, rarely fatal. Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are frequently used as part of any antiretroviral combination therapy. Side effects and low resistance barrier of fi rst-generation NNRTIs (e.g., nevirapine and efavirenz) have been overcome with rilpivirine (RPV), and the last NNRTI approved for the treatment of HIV infection...
October 2017: AIDS Reviews
https://www.readbyqxmd.com/read/29062862/high-rates-of-occult-hepatitis-b-virus-infection-in-hiv-positive-individuals-initiating-antiretroviral-therapy-in-botswana
#20
Kathleen Ryan, Motswedi Anderson, Ivayla Gyurova, Lilliam Ambroggio, Sikhulile Moyo, Teresa Sebunya, Joseph Makhema, Richard Marlink, Max Essex, Rosemary Musonda, Simani Gaseitsiwe, Jason T Blackard
BACKGROUND: Hepatitis B surface antigen (HBsAg)-negative but hepatitis B virus (HBV) DNA-positive infection-known as occult hepatitis B infection (OBI)-occurs in 1% to >15% of HIV-positive individuals in the United States and South Africa, respectively. However, there are no data on OBI from Botswana, a country known to be hyperendemic for chronic HBV infection and to have a significant HIV burden. METHODS: Two hundred seventy-two adults enrolled in an HIV treatment study of tenofovir/emtricitabine as the nucleoside backbone who were previously determined to be HBsAg negative were tested for HBV DNA at baseline and 1 year after initiation of highly active antiretroviral therapy (HAART)...
2017: Open Forum Infectious Diseases
keyword
keyword
114588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"